Thursday, October 04, 2007 8:51:39 PM
link to the Q and A part of the Orbec Odac panel
people can read all of the positive statements Pazdur made during the proceedings.
Remember, if he likes the drug and asks for another trial it will never be approved. the fred Hutchinson center supplied 47 percent of the patients. since they use the corn oil they would not be able to do a placebo trial so a new trial would never recruit patients.
http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4301t1-Part4.pdf
people can read all of the positive statements Pazdur made during the proceedings.
Remember, if he likes the drug and asks for another trial it will never be approved. the fred Hutchinson center supplied 47 percent of the patients. since they use the corn oil they would not be able to do a placebo trial so a new trial would never recruit patients.
http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4301t1-Part4.pdf
Recent SNGX News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:16:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:14:13 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:12:12 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:10:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:05:35 PM
- Soligenix Announces Recent Updates and First Quarter 2026 Financial Results • PR Newswire (US) • 05/08/2026 11:30:00 AM
- SNGX Phase 3 Trial Halted — HyBryte Setback Puts Strategy in Question • IH Market News • 04/28/2026 03:06:46 PM
- SNGX Phase 3 Trial Halted on HyBryte • IH Market News • 04/28/2026 03:06:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:30:13 AM
- Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma • PR Newswire (US) • 04/28/2026 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 • PR Newswire (US) • 03/23/2026 11:30:00 AM
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" • PR Newswire (US) • 03/19/2026 11:30:00 AM
